Loading…
Jfl Life Sciences (JFLLIFE)₹12.90+4.45%Pharmaceuticals
In the Jun 2026 quarter (standalone), Jfl Life Sciences reported sales of ₹11.15 Cr, down 4.2% from Jun 2025, and net profit of ₹1.10 Cr, up 48.6% year on year. For the year to Mar 2026, sales were ₹131 Cr and net profit ₹5.99 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.77 | 9.57 | 39.64 | 21.33 | 11.76 | 11.64 | 30.03 | 26.94 | 63.23 | 11.15 |
| Expenses | 20.07 | 6.46 | 36.98 | 19.85 | 10.31 | 9.63 | 26.90 | 23.40 | 59.33 | 8.98 |
| Operating Profit | 1.54 | 3.05 | 2.40 | 1.34 | 1.37 | 1.92 | 2.90 | 3.34 | 3.50 | 2.08 |
| OPM % | 7.1% | 32.0% | 6.1% | 6.3% | 11.7% | 16.6% | 9.7% | 12.4% | 5.5% | 18.8% |
| Other Income | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.01 |
| Interest | 0.08 | 0.25 | 0.26 | 0.19 | 0.32 | 0.23 | 0.43 | 0.37 | 1.02 | 0.29 |
| Depreciation | 0.12 | 0.25 | 0.25 | 0.17 | 0.37 | 0.27 | 0.28 | 0.28 | 0.28 | 0.33 |
| Profit before tax | 1.38 | 2.57 | 1.91 | 1.00 | 0.70 | 1.44 | 2.22 | 2.72 | 2.26 | 1.50 |
| Tax % | 13.1% | 25.4% | 23.1% | 25.2% | 87.0% | 48.2% | 10.8% | 25.1% | 26.2% | 25.5% |
| Net Profit | 1.18 | 1.90 | 1.44 | 0.73 | 0.07 | 0.74 | 1.96 | 2.01 | 1.65 | 1.10 |
| EPS (Rs) | 0.17 | 0.28 | 0.21 | 0.10 | 0.00 | 0.10 | 0.29 | 0.30 | 0.24 | 0.16 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 32.09 | 30.12 | 33.14 | 34.11 | 43.12 | 47.15 | 82.23 | 131 | 131 |
| Expenses | 29.90 | 27.93 | 30.93 | 27.89 | 38.89 | 41.83 | 73.71 | 120 | 119 |
| Operating Profit | 0.99 | 1.99 | 1.99 | 4.99 | 3.99 | 4.99 | 7.99 | 11.99 | 11.82 |
| OPM % | 4.2% | 6.0% | 6.9% | 15.9% | 9.0% | 9.9% | 9.9% | 9.0% | 9.0% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.99 | 2.01 | 1.01 | 0.00 | 0.00 | 0.04 |
| Interest | 0.99 | 0.99 | 0.99 | 1.99 | 0.99 | 0.99 | 0.99 | 1.99 | 2.11 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 1.17 |
| Profit before tax | 0.00 | 0.00 | 1.01 | 4.01 | 4.01 | 4.01 | 6.01 | 9.02 | 8.70 |
| Tax % | 28.0% | 29.0% | 27.0% | 26.0% | 25.0% | 13.0% | 32.0% | 26.0% | — |
| Net Profit | 0.00 | 0.00 | 0.99 | 2.99 | 2.99 | 2.99 | 3.99 | 5.99 | 6.72 |
| EPS (Rs) | 1.24 | 1.49 | 1.49 | 0.58 | 0.42 | 0.49 | 0.62 | 0.96 | 0.99 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 8.0% | 0.0% | 0.0% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.50 | 7.98 | 10.98 | 10.99 | 32.91 | 32.93 |
| Reserves | 4.98 | 4.98 | 5.97 | 2.99 | 20.92 | 24.90 | 5.98 | 12.95 |
| Borrowings | 7.97 | 8.98 | 16.94 | 15.97 | 6.99 | 6.00 | 10.98 | 21.96 |
| Other Liabilities | 2.99 | 9.95 | 4.98 | 20.89 | 9.96 | 14.93 | 21.89 | 38.81 |
| Total Liabilities | 15.94 | 23.91 | 28.89 | 47.83 | 48.85 | 56.82 | 71.76 | 106 |
| Fixed Assets | 1.99 | 4.99 | 5.99 | 6.98 | 6.98 | 11.97 | 11.98 | 14.97 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 13.95 | 18.92 | 22.90 | 40.85 | 41.87 | 43.85 | 59.78 | 91.68 |
| Inventories | 2.01 | 4.01 | 6.01 | 15.04 | 13.03 | 16.05 | 23.05 | 35.09 |
| Trade receivables | 9.99 | 13.01 | 12.01 | 19.99 | 21.99 | 24.98 | 34.99 | 52.98 |
| Cash & equivalents | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 |
| Total Assets | 15.94 | 23.91 | 28.89 | 47.83 | 48.85 | 56.82 | 71.76 | 106 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −2.99 | 2.99 | −5.99 | 1.99 | −9.01 | 8.01 | −3.99 | −4.01 |
| Cash from investing activity | −1.01 | −3.01 | −2.01 | −1.01 | 1.01 | −6.01 | 0.00 | −4.01 |
| Cash from financing activity | 3.99 | 0.00 | 6.98 | −0.99 | 7.98 | −1.99 | 3.99 | 8.97 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 |
| Capex | 0.60 | 2.77 | 1.71 | 1.68 | 0.00 | 6.08 | 0.39 | 3.37 |
| Free cash flow | −4.01 | 0.00 | −8.03 | 1.01 | −9.02 | 2.01 | −4.01 | −8.02 |
| CFO / OP % | −225.0% | 176.9% | −268.0% | 40.9% | −206.1% | 184.9% | −31.1% | −37.1% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 110 | 152 | 131 | 214 | 191 | 196 | 154 | 147 |
| Inventory days | 20 | 51 | 71 | 211 | 129 | 148 | 127 | 109 |
| Days payable | 17 | 121 | 57 | 217 | 75 | 91 | 97 | 92 |
| Cash conversion cycle | 115 | 83 | 146 | 208 | 246 | 254 | 186 | 165 |
| Working capital days | 61 | 6 | 73 | 116 | 220 | 180 | 123 | 102 |
| ROCE % | — | 12.0% | 10.0% | 23.0% | 15.0% | 11.0% | 16.0% | 18.0% |
For the Jun 2026 quarter, Jfl Life Sciences reported sales of ₹11.15 Cr, down 4.2% year on year and net profit of ₹1.10 Cr, up 48.6% year on year. The operating margin was 18.8%.
Jfl Life Sciences' sales for the year to Mar 2026 were ₹131 Cr; over the last twelve months they were ₹131 Cr.
Net profit for the year to Mar 2026 was ₹5.99 Cr, and ₹6.72 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.99.
Jfl Life Sciences reported borrowings of ₹21.96 Cr at Mar 2026, against cash and equivalents of ₹0.99 Cr.
Cash from operations was −₹4.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹8.02 Cr.